Christoph Kapitza

10PUBLICATIONS
15CO-AUTHORS
PharmacogenomicsMolecular targetsNutritional epidemiologyPharmaceutical delivery technologiesMedical biochemistry - carbohydrates
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Dec 17, 2022
Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906.

Arvid Jungnik, Jorge Arrubla Martinez, Leona Plum-Mörschel

|Jan 05, 2022
Acute effects of linagliptin on intact and total glucagon-like peptide-1 and gastric inhibitory polypeptide levels in insulin-dependent type 2 diabetes patients with and without moderate renal impairment.

Juris J Meier, Daniel R Quast, Michael A Nauck

|Dec 27, 2021
Effect of upper gastrointestinal disease on the pharmacokinetics of oral semaglutide in subjects with type 2 diabetes.

Juris J Meier, Charlotte Granhall, Ulrike Hoevelmann

|Oct 04, 2021
Ultra-rapid lispro shows faster pharmacokinetics and reduces postprandial glucose excursions versus Humalog® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early phase study.

Jennifer Leohr, Christof Kazda, Rong Liu

|Jun 30, 2021
Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short- and long-acting glucagon-like peptide-1 receptor agonists in type 2 diabetes.

Daniel R Quast, Michael A Nauck, Nina Schenker

|Nov 25, 2020
A single-dose euglycaemic clamp study in two cohorts to compare the exposure of SAR341402 (insulin aspart) Mix 70/30 with US- and European-approved versions of insulin aspart Mix 70/30 and SAR341402 rapid-acting solution in subjects with type 1 diabetes.

Christoph Kapitza, Leszek Nosek, Wolfgang Schmider

Pageof 2

Frequent Collaborators

5 joint publications

Juris J Meier

3 joint publications

Michael A Nauck

2 joint publications

Jennifer Leohr

2 joint publications

Daniel R Quast